4,4-正丙基环己酮 | 123018-62-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4,4-正丙基环己酮
• 中文别名: 4,4-二丙基环己烷酮
• 英文名称: 4,4-di-n-propylcyclohexanone
• 英文别名: 4,4-dipropylcyclohexanone；4,4-Dipropylcyclohexan-1-one
• CAS: 123018-62-2
• 化学式: C₁₂H₂₂O
• mdl: MFCD00269982
• 分子量: 182.306
• InChiKey: RPZMJERYWZOQJX-UHFFFAOYSA-N

物化性质

• 沸点：
  57-60°C/0.5 mm
• 密度：
  0.870±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.916
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914299000

反应信息

• 作为反应物：
  描述：

  4,4-正丙基环己酮 在 乙酸铵 、 盐酸 、 lithium aluminium tetrahydride 、 水 、 乙酸酐 、 溶剂黄146 作用下， 以 乙醚 、 乙醇 、 水 、 甲苯 为溶剂， 反应 96.0h， 生成 2-(3-哌啶-1-基丙基)-8,8-二丙基-2-氮杂螺[4.5]癸烷
  参考文献：
  名称：

  Antiarthritic and supressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents

  摘要：

  Spirogermanium (1; 8,8-diethyl-N,N-dimethyl-2-aza-8- germaspiro[4.5]decane-2-propanamine dihydrochloride) is a potent cytotoxic agent in vitro which has demonstrated limited activity in experimental animal tumor models. Subsequently, it has been reported that spirogermanium has antiarthritic and suppressor cell-inducing activity. We have synthesized a series of substituted 8-hetero-2-azaspiro[4.5]decane and 9-hetero-3-azaspiro[5.5]undecane analogues of spirogermanium to identify the heteroatom requirements for in vivo antiarthritic and suppressor cell-inducing activity. This structure-activity relationship study has identified that appropriately substituted silicon and carbon analogues of spirogermanium retain both antiarthritic and immunosuppressive activity, with the 8,8-dipropyl (carbon) analogue being among the most active. Following the identification of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine++ + dihydrochloride (9) as a more active analogue than spirogermanium, a series of 8,8-dipropyl analogues with various amine substituents were synthesized. A number of these analogues had activity similar to that of 9. A correlation between activity in the adjuvant arthritic rat and the ability to induce suppressor cells (r = 0.894, p less than 0.001) suggests an association between the two pharmacologic effects. While the precise biochemical mechanism(s) for the pharmacological activity is unclear, these data suggest that compounds within this series, e.g., N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine++ + dihydrochloride, may provide effective therapy in diseases of autoimmune origin and/or the prevention of rejection in tissue transplantation.

  DOI：

  10.1021/jm00173a010
• 作为产物：
  描述：

  4,4-双丙基环己酮 在 钯 作用下， 以 乙醇 为溶剂， 以to give 4,4-dipropylcyclohexanone的产率得到4,4-正丙基环己酮
  参考文献：
  名称：

  N-substituted phenylacetamide derivative and pharmaceutical composition containing the same

  摘要：

  本发明提供以下化合物(I)：其中R1是甲氧基、羟基或氢原子；R2是氢原子、C1-4烷基、C1-4烷基羰基或芳基羰基；D是以下公式(A)、(B)或(C)的基团。该化合物可用作治疗神经病性疼痛或由类风湿性关节炎和骨关节炎等各种疾病引起的疼痛和炎症的药物。

  公开号：

  US07767854B2

文献信息

• [EN] TETRAHYDROCARBOLINE DERIVATIVES AS EG5 INHIBITORS<br/>[FR] DÉRIVÉS DE TÉTRAHYDROCARBOLINE COMME INHIBITEURS DE L'EG5
  申请人：SANOFI SA

  公开号：WO2011084439A1

  公开（公告）日：2011-07-14

  The present invention relates to substituted tetrahydro-β-carbolines and substituted tetrahydro-γ-carbolines. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are inhibitors of Eg5 kinesin. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of diseases.

  本发明涉及替代的四氢-β-咔啉和替代的四氢-γ-咔啉。本发明还涉及制备这些化合物的方法，包括新颖的中间体。本发明的化合物是Eg5肌动蛋白的抑制剂。因此，本发明的化合物在药物制剂中具有用途，特别是在治疗和/或预防疾病方面。
• The Organocatalytic Approach to Enantiopure 2<i>H</i>- and 3<i>H</i>-Pyrroles: Inhibitors of the Hedgehog Signaling Pathway
  作者：Lisa Kötzner、Markus Leutzsch、Sonja Sievers、Sumersing Patil、Herbert Waldmann、Yiying Zheng、Walter Thiel、Benjamin List

  DOI：10.1002/anie.201602932

  日期：2016.6.27

  indolization and a [1,5]‐alkyl shift. Catalyzed by the chiral phosphoric acid STRIP, good to excellent yields and enantioselectivities could be obtained. Remarkably, biological evaluation reveals one of these novel 2H‐pyrroles to be a potent but nontoxic inhibitor of the Hedgehog signaling pathway by binding to the Smoothened protein.

  据报道，由螺环磷酸催化的对映体富集的2 H-和3 H-吡咯的发散方法是利用Fischer型吲哚化和[1,5]-烷基转移。通过手性磷酸STRIP催化，可获得良好至优异的收率和对映选择性。值得注意的是，生物学评估显示，这些新的2 H-吡咯之一通过与平滑蛋白结合，是一种有效的Hedgehog信号通路抑制剂，但无毒。
• 一种烯醇化与亚乙基化联合反应方法
  申请人：中山百灵生物技术股份有限公司

  公开号：CN114181274B

  公开（公告）日：2023-06-09

  本发明公开了一种烯醇化与亚乙基化联合反应方法，包括以下步骤：于35～45℃在混合碱基和有机溶剂的存在下进行α‑烷基酮类底物与硅基形成烯醇硅醚的烯醇化反应；将得到的烯醇硅醚产物于‑35～15℃与乙醛试剂在三氟化硼和有机溶剂的存在下发生亚乙基化反应得到亚乙基化产物；所述的混合碱基为三乙胺、2,2‑甲基吗啉、叔丁胺中的两种或两种以上；所述混合碱基与α‑烷基酮类底物的物质的量比为1～3：1。本发明不仅保护稳定了反应的中间体烯醇化物，还催化了烯醇化与路易斯酸的反应进程，反应选择性好，使得烯醇化反应产物可以稳定地发生区域专一性的亚乙基化反应。
• Immunomodulatory azaspiranes
  申请人：SmithKline Beecham Corporation

  公开号：US04963557A1

  公开（公告）日：1990-10-16

  A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an effective amount of an azaspirane derivative, a method of treating an animal in need of immunomodulation which comprises administering to such animal an effective amount of an azaspirane derivative, and certain azaspirane derivatives.

  一种含有药用载体或稀释剂和有效量的氮杂环丙烷衍生物的制药组合物，一种治疗需要免疫调节的动物的方法，其中包括向该动物投与有效量的氮杂环丙烷衍生物，以及某些氮杂环丙烷衍生物。
• N-substituted phenylacetamide derivative and pharmaceutical composition containing the same
  申请人：Morie Toshiya

  公开号：US20090082463A1

  公开（公告）日：2009-03-26

  The invention provides the following compound (I): wherein R 1 is methoxy group, hydroxyl group or hydrogen atom; R 2 is hydrogen atom, C 1-4 alkyl group, C 1-4 alkylcarbonyl group or arylcarbonyl group; D is a group of the following formula (A), (B), or (C). The compound is useful as a medicament for treating neuropathic pain or pain caused by various diseases such as rheumatoid arthritis and osteoarthritis, and inflammation.

  本发明提供以下化合物（I）：其中，R1是甲氧基、羟基或氢原子；R2是氢原子、C1-4烷基、C1-4烷基羰基或芳基羰基；D是下式（A）、（B）或（C）的基团。该化合物可用作治疗神经病理性疼痛或由风湿性关节炎和骨关节炎等各种疾病引起的疼痛和炎症的药物。